Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors

PURPOSE: RC48 contains the novel humanized anti-HER2 antibody hertuzumab conjugated to MMAE via a cleavable linker. A phase I study was initiated to evaluate the toxicity, MTD, PK, and antitumor activity of RC48 in patients with HER2-overexpressing locally advanced or metastatic solid carcinomas, pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yingying, Wang, Yakun, Gong, Jifang, Zhang, Xiaotian, Peng, Zhi, Sheng, Xinan, Mao, Chenyu, Fan, Qingxia, Bai, Yuxian, Ba, Yi, Jiang, Da, Yang, Fen, Qi, Changsong, Li, Jian, Wang, Xicheng, Zhou, Jun, Lu, Ming, Cao, Yanshuo, Yuan, Jiajia, Liu, Dan, Wang, Zhenghang, Fang, Jianmin, Shen, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205919/
https://www.ncbi.nlm.nih.gov/pubmed/33945049
http://dx.doi.org/10.1007/s10120-021-01168-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205919/
https://www.ncbi.nlm.nih.gov/pubmed/33945049
http://dx.doi.org/10.1007/s10120-021-01168-7

Ejemplares similares